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Abstract 
Cerebral hyperperfusion is a relatively rare syndrome with significant and potentially preventable clinical conse-
quences. The pathophysiology of cerebral hyperperfusion syndrome (CHS) may involve dysregulation of the cerebral 
vascular system and hypertension, in the setting of increase in cerebral blood flow. The early recognition of CHS is 
important to prevent complications such as intracerebral hemorrhage. This review will focus on CHS following carotid 
endarterectomy and carotid artery stenting. We will discuss the typical clinical features of CHS, risk factors, pathophysi-
ology, diagnostic modalities for detection, identification of patients at risk, and prevention and treatment. Although 
currently there are no specific guidelines for the management of CHS, identification of patients at risk for CHS and 
aggressive treatment of hypertension are recommended.
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Background
Cerebral hyperperfusion syndrome (CHS) is a relatively 
rare condition after carotid endarterectomy (CEA) or 
carotid artery stenting (CAS) but is potentially prevent-
able. CHS may be defined as focal cerebral damage fol-
lowing a revascularization procedure, usually as a result 
of hyperperfusion. Bouri et al. suggest the following four 
criteria to define post-CEA CHS [1]:
(1) Occurrence within 30 days post-CEA;
(2)  Clinic features such as new onset headache, seizure, 
hemiparesis, and glasgow coma scale (GCS) <15 or 
radiological features including cerebral edema or 
intracerebral hemorrhage (ICH);
(3)  Evidence of hyperperfusion (defined as a cerebral 
blood flow [CBF]  >100  % or perioperative values) 
on imaging studies [e.g., transcranial doppler, sin-
gle photon emission computerized tomography 
(SPECT) or magnetic resonance perfusion (MRP)] 
or systolic blood pressure >180 mmHg [2]; and
(4) No evidence of new cerebral ischemia, postopera-
tive carotid occlusion and metabolic or pharmaco-
logic cause.
Hyperperfusion has been reported in 0.2 to 18.9  % of 
cases following CEA [2]. The incidence of CHS, however, 
is much less frequent. Moulakakis and colleagues in a ret-
rospective review of 4689 patients undergoing CEA and 
4446 patients undergoing CAS reported the incidence of 
CHS and ICH following CAS as 1.16 and 0.74 %, respec-
tively, whereas following CEA the incidence of CHS and 
ICH was 1.9 and 0.37 % [3].
The term CHS has often been used interchangeably 
with cerebral reperfusion injury, and some authors argue 
that the latter term is more appropriate.
The pathophysiology of reperfusion related injury is not 
entirely clear, however, it is believed that dysregulation of 
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the cerebral vascular system and hypertension resulting 
in an increase of CBF play a significant role.
Early recognition of CHS is important as it may be 
reversed at an early stage. Initially the edema associated 
with CHS is reversible, however, if CHS progresses to 
ICH the prognosis is not nearly as favorable as up to 30 % 
of patients remain at least partially disabled, and mortal-
ity rates are up to 50 % [4, 5].
This review will focus on CHS following CEA and CAS. 
Specifically, we will discuss the pathophysiology, diagnos-
tic modalities for detection and identification of patients 
at risk, and prevention and treatment of CHS.
Pathophysiology
The exact mechanism of CHS after CAS or CEA remains 
unclear but seems to be multi-factorial.
Impairment of autoregulation
The normal brain has the ability to maintain constant 
intracranial pressure by an autoregulatory mechanism, 
when a change in blood flow occurs. Waltz in 1968 first 
described the impact of changes of systemic blood pres-
sure on CBF in ischemic and non-ischemic cortex in a 
cat model of middle cerebral artery occlusion [6]. In non-
ischemic cortex, cortical blood flow remained constant 
despite changes in systemic blood pressure, whereas in 
ischemic cortex, cortical blood flow varied directly with 
systemic blood pressure from 35 to 120  mm Hg [6]. 
Waltz hypothesized that cerebral ischemia produces an 
impairment of cerebral autoregulation [6].
Sundt and colleagues reviewed CBF in 1145 patients 
who underwent carotid endarterectomy from 1972 to 
1981 [7]. They found that the most common causes of 
perioperative neurologic complications were intraop-
erative embolization and postoperative hyperperfusion 
phenomenon. Six patients had severe unilateral head-
ache postoperatively and the mean increase in CBF was 
40  ml/100  g/min. Mean increase in CBF for the five 
patients with ICH was 47 ml/100 g/min. Whereas mean 
increases in CBF for all other patients without these post-
operative neurologic complications was 1 to 5 ml/100 g/
min. They concluded that neurological complications 
including CHS are related to increase of cerebral perfu-
sion after recanalization of the previous narrowed carotid 
artery [7].
Bernstein and colleagues described a 56-year-old man 
with a high-grade left carotid stenosis who had left CEA 
[8]. The patient developed a severe left-sided headache 
on the first postoperative day. On the second postopera-
tive day he had grand mal seizures. He had right hemi-
paresis and died of a left ICH on the sixth postsurgical 
day. At postmortem examination, the small arteries and 
arterioles of the left cerebral cortex showed reactive 
edema and hyperplasia of endothelial cells, extravasa-
tion of erythrocytes, and fibrinoid necrosis [8]. These 
features of altered vascular pathology are similar to those 
seen in the brain with malignant hypertension. They sur-
mised that chronic cerebral ischemia distal to high-grade 
carotid artery stenosis led to chronic vasodilatation, loss 
of autoregulation, and a consequent absence of arterial 
vasoconstriction to protect the capillary bed [8].
Postoperative hypertension in the setting of impaired 
autoregulation may cause an increase in cerebral perfu-
sion pressure (CPP) as CPP is dependent on mean arte-
rial pressure. Acute increase in CPP in areas of infarcted/
necrotic or hypoperfused tissue can lead to ICH. This 
may be more pronounced when there is impaired vasore-
activity of cerebral vasculature and inability of arterioles 
to constrict in the setting of increased perfusion resulting 
in ICH [9].
Chronic hypertension, microangiopathy and blood brain 
barrier damage
In general, patients with severe carotid artery steno-
sis often have underlying systemic hypertension and 
undergo CEA to reduce the risk of stroke in a vascular 
bed that may be subject to chronic cerebral ischemia. 
Baseline chronic hypertension might play a major role 
in the development of CHS. Preoperative longstanding 
hypertension leads to endothelial dysfunction and micro-
angiopathy which can result in a breakdown of the blood 
brain barrier (BBB). Breakdown of the BBB was observed 
previously in an animal model of cerebral hyperperfusion 
[10]. There is evidence of extravasation of serum albu-
min after BBB breakdown in animal experiments show-
ing that there is activation of the transforming growth 
factor beta (TGFβ) signaling pathway. This results in the 
induction of cerebral edema and seizure-like activity in 
patients with no prior edema [11]. Damaging the BBB 
allows extravasation of toxins and edema into the brain 
parenchyma. Additionally, underlying lipohyalinosis in 
the setting of hypertension can lead to the development 
of Charcot–Bouchard aneurysms and the subsequent 
occurrence of ICH [9].
Role of nitric oxide and free radicals in impairment 
of autoregulation and BBB dysfunction
A presumed mediator of impairment of autoregula-
tion and dysfunction of BBB in CHS is nitric oxide, 
which leads to vasodilatation and increases in cerebral 
vessel permeability [12]. Dohare and colleagues dem-
onstrated that high levels of nitric oxide generated by 
nitric oxide synthase isoforms are responsible, at least 
in part, for exacerbating the neuronal damage in the 
rat model of middle cerebral artery ischemia/reperfu-
sion with an intraluminal filament [13]. Increased nitric 
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oxide expression and free radical production may last up 
to 48 h after reperfusion. It has been shown that oxygen-
derived free radicals associated with CEA play a role in 
furthering ischemic injury even after short-term carotid 
artery clamping [14, 15].
Baroreceptor dysfunction
Baroreceptor dysfunction is also known as baroreflex 
failure syndrome (BFS). This can be related to barorecep-
tor denervation after bilateral CEA and may lead to CHS. 
Baroreceptor dysfunction can also cause a progressive 
increase in blood pressure after CEA which is challeng-
ing to control even with blood pressure lowering therapy. 
Fluctuations in blood pressure after CEA can last up to 
12  weeks due to baroreceptor denervation. One study 
showed that 6.6 % of patients with bilateral CEA devel-
oped CHS as compared to 1.1 % of patients with unilat-
eral CEA. Therefore, contralateral CEA performed within 
3 months of CEA on the other side increases the risk of 
CHS [16–18].
Sometimes, there is carotid baroreceptor stimula-
tion during a carotid artery endovascular procedure via 
a balloon or carotid stent manipulation. The stimulation 
results in transient bradycardia and hypotension lead-
ing to cerebral ischemia. In some situations, the stimu-
lation can be quite prolonged even more than that seen 
in patients with CEA during clamping of the internal 
carotid artery. These patients are at risk of CHS due to 
rebound arterial hypertension and also due to cerebral 
ischemia that occurs during the procedure [3, 19].
Key points about the pathophysiology of CHS are listed 
in Table 1.
Imaging modalities used in the prediction 
and diagnosis of cerebral hyperperfusion 
syndrome
There are several imaging modalities and techniques 
used to investigate patients for CHS. These include but 
are not limited to transcranial doppler (TCD), comput-
erized tomography (CT), magnetic resonance imaging 
(MRI), MR perfusion (MRP) and single-photon-emission 
CT (SPECT).
Transcranial doppler
TCD is the most commonly and widely available tech-
nique that can be used for the evaluation and predic-
tion of the risk of CHS in preoperative, perioperative 
and postoperative phases. The main advantage of TCD 
is that it is non-invasive and provides real-time informa-
tion. One may observe preoperative cerebral hypoperfu-
sion and postoperative cerebral hyperperfusion. Also, 
TCD detects cerebral embolic signals that may lead to 
ischemia [2, 3].
TCD measures CBF velocity in the middle cerebral 
artery (MCA) and can be of value in predicting a differ-
ence in CBF in patients with CHS. Auto-regulation has 
no effect on the diameter of the MCA. Therefore, changes 
in MCA flow velocity correlate nicely with changes in 
MCA perfusion. If there is a significant reduction in CBF 
velocity of intracranial blood vessels in the preoperative 
phase as compared to baseline values, it will be associ-
ated with postoperative hyperperfusion. On the other 
hand, a 1.5-fold postoperative increase of MCA mean 
flow velocity compared with preoperative levels may pre-
dict the occurrence of CHS [18, 20].
Other TCD criteria for the prediction of postoperative 
hyperperfusion in patients with recent CEA have been 
defined. These include low perioperative distal carotid 
artery pressure (<40  mmHg), and an increase in peak 
blood flow velocity and pulsatility index of >100 % after 
declamping of the carotid artery in CEA [18, 21, 22].
Moreover, cerebral vasoreactivity can predict the risk 
of CHS, and this can be measured using TCD. In a nor-
mal person, the administration of carbon dioxide or 
acetazolamide will lead to a rapid increase in CBF rang-
ing from 20 to 80  % due to dilatation of cerebral blood 
vessels. In patients with chronic cerebral ischemia, the 
cerebral blood vessels are already maximally dilated, and 
there is no significant change in CBF after the adminis-
tration of carbon dioxide or acetazolamide. This is called 
Table 1 Key factors in  the pathophysiology of  cerebral 
hyperperfusion syndrome [1, 2, 12–23]
Factor Pathophysiology
Impaired auto-regulation and 
baroreceptor dysfunction
Fluctuations in blood pressure
Post-operative hypertension
 Increase in cerebral perfusion 
pressure
 Risk of intracerebral hemorrhage in 
hypo-perfused tissues
 Transient bradycardia and changes 
in cerebral blood flow
Chronic hypertension, microangi-
opathy and blood brain barrier
 Endothelial dysfunction and micro-
angiopathy
 Increased vessel permeability
 Breakdown of blood brain barrier
 Extravasation of albumin
 Activation of TGFβ signaling 
pathways
 Release of nitric oxide
Formation of free radicals  Lipid peroxidation
 Vascular endothelial damage
 Cerebral edema
Degree of chronic carotid stenosis  Chronic hypoperfusion
 Endothelial damage
 Imbalance of vasodilatory chemi-
cals
Collateral circulation  Changes in cerebral blood flow
 Cerebral vasoreactivity
Page 4 of 8Farooq et al. Exp & Trans Stroke Med  (2016) 8:7 
low or impaired cerebral hemodynamic reserve. Using 
TCD, patients with low preoperative cerebrovascular 
reserve are at risk of developing cerebral hyperperfusion 
and CHS [18, 23, 24].
Also, it has been shown that TCD-derived low intra-
operative distal internal carotid artery pressure (d ICAP) 
(<40  mmHg) has a high predictive value for postopera-
tive hyperperfusion and CHS [21]. Moreover, a signifi-
cant increase in mean internal carotid artery volume flow 
(MICAVF) has been reported in patients with CHS dur-
ing the symptomatic period [3, 17].
The limitations of TCD should be kept in mind, and 
these include but are not limited to various techni-
cal problems such as an insufficient cranial window for 
insonation, variations of intracranial blood vessels form-
ing the circle of Willis making insonation difficult, and 
cervical vessels which can affect velocities of intracranial 
vessels.
CT
CT of the brain completed right after CEA can be com-
pletely normal in patients with CHS. Later on, find-
ings develop which may include diffuse cerebral edema, 
patchy white matter changes, mass effect, and intracer-
ebral hemorrhage (Fig. 1). These changes are sometimes 
more marked in the posterior circulation involving pos-
terior parietal-occipital regions as there is a lack of sym-
pathetic innervation in the posterior circulation of the 
brain. Overall, however, CT brain before or after CEA is 
of limited value for the evaluation of CHS as such find-
ings can be non-specific. Thus, CT brain is not a useful 
tool for prediction of CHS [2, 3].
MRI
MRI of the brain is more sensitive to detect ischemic 
changes but not necessarily to predict the risk of CHS. 
MRI abnormalities can be similar to those seen on CT of 
the brain including white matter edema, focal infarction 
or hemorrhage (Fig. 2). However, in many cases of CHS, 
MRI of the brain may be unremarkable [2, 3].
MR perfusion
MR perfusion scan can show a difference in CBF in the 
cerebral hemispheres. Measurement of preoperative CBF 
by using perfusion-weighted imaging can help identify 
patients at risk of cerebral hyperperfusion after CEA in 
the absence of contralateral internal carotid artery ste-
nosis. Fukuda et  al. showed a significant correlation 
between preoperative CBF and increase in CBF immedi-
ately after CEA (p  <  0.0001). They studied the relation-
ship between hyperperfusion immediately after CEA and 
elevated preoperative cerebral blood volume and noted 
that no patient with normal preoperative cerebral blood 
volume showed post-CEA hyperperfusion. Furthermore, 
elevated preoperative cerebral blood volume was the only 
significant independent predictor of post-CEA hyperper-
fusion [2, 3, 25].
Single‑photon‑emission CT (SPECT)
Single-photon-emission CT of the brain is a sensitive 
method to identify patients at risk of hyperperfusion 
after CEA and for recognizing CHS. It helps to differenti-
ate between brain ischemia and hyperperfusion. Similar 
to TCD, it can help determine CBF reserve after carbon 
dioxide or acetazolamide administration and also detect 
postoperative cerebral hyperperfusion, especially if 
hyperperfusion persists between the 1st and 3rd postop-
erative day. Ogasawara et al. showed that intraoperative 
MCA blood flow velocity monitoring by using TCD was 
a less reliable method to detect cerebral hyperperfusion 
after CEA than postoperative MCA blood flow velocity 
monitoring by SPECT. In this study, TCD monitoring 
Fig. 1 CT scan of the brain (axial sequence) shows an area of hyper-
density in the right frontal lobe suggestive of intracerebral hemor-
rhage (arrow) in a 67 year old woman who underwent right carotid 
endarterectomy (CEA) for the treatment of a 95 % right ICA stenosis. 
The patient post-operatively developed headache, photophobia and 
intermittent dizziness. This CT brain was done almost 24 h after the 
CEA. Systolic blood pressure was in the 170 s mm Hg and difficult to 
control as after CEA there was thought to be a clamp injury to the 
right carotid artery bulb. However, the patient did well clinically and 
at her 3 month follow up office visit, she had no residual neurological 
deficits
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could not be completed in one out of seven patients diag-
nosed with post-CEA hyperperfusion on SPECT imaging 
and who later developed CHS. SPECT technique is supe-
rior to TCD when there is occlusion or hemodynamically 
significant stenosis of the ipsilateral MCA [26–28].
Features of key imaging modalities in the diagnosis of 
CHS are listed in Table 2.
Prevention and treatment of cerebral 
hyperperfusion syndrome
Preventive strategies for CHS include proper blood pres-
sure control in the perioperative period, and considera-
tion of timing of surgery, type of anesthesia, and use of 
free radical scavengers. These strategies are discussed 
below.
Blood pressure control
An important factor in the prevention of CHS is proper 
control of blood pressure. It may be prudent to carefully 
monitor blood pressure in patients with increased CBF as 
hypertension may subsequently develop postoperatively 
even in normotensive patients. Blood pressure control in 
patients with CHS may be challenging, and even when 
there is normal blood pressure, CHS can occur. There-
fore, whereas it is recommended to have careful control of 
blood pressure, there are no definitive guidelines about the 
target blood pressure in these patients and for how long 
blood pressure needs to be controlled [2, 18, 21, 29, 30].
Fig. 2 MRI of the brain (axial sequence) gradient recall echo (GRE) image shows hypointense foci in the right frontal region consistent with hemor-
rhage (arrows) in the same patient mentioned in Fig. 1
Table 2 Key imaging modalities used in  the diagnosis 
of cerebral hyperperfusion syndrome [1–3, 9, 26–32]
Imaging modality Key role and findings on imaging studies
Transcranial doppler  Non-invasive and provides real time information
 Detect cerebral embolic signals during CEA
 Accurately measures cerebral blood flow velocity
 Measurement of cerebral vasoreactivity
 Determination of distal internal carotid artery 
pressure
 Changes in mean internal carotid artery volume 
flow
CT and MRI brain Detection of :
 Ischemic changes and focal infarction
 White matter edema
 Intracerebral hemorrhage
MR perfusion  Measurement of cerebral blood flow/volume and 
inter-hemispheric differences
 Contralateral carotid artery stenosis and flow 
difference
SPECT of the brain  Cerebral blood flow measurement
 CO2 and acetazolamide studies to determine flow 
changes
 Accurate measurement of middle cerebral artery 
blood flow velocity
Page 6 of 8Farooq et al. Exp & Trans Stroke Med  (2016) 8:7 
One should be cautious when selecting a drug for 
blood pressure control in these patients as some of the 
anti-hypertensives with vasodilatory effects may worsen 
the outcome. Medications in the latter group include cal-
cium channel blockers, sodium nitroprusside, glycerol 
trinitrate, and angiotensin II inhibitors. Beta-blockers 
reduce arterial blood pressure and have little effect on 
the intracranial pressure within the autoregulatory range. 
Therefore, beta-blockers potentially can be used to treat 
hypertension in patients with brain injury. A limitation 
to some of the early generation beta-blockers is that they 
may be associated with blood pressure variability. How-
ever, other medications which may be more suitable for 
these patients include mixed alpha-adrenergic antago-
nists and beta-adrenergic antagonists such as labetalol. 
These medications help reduce cerebral perfusion pres-
sure and mean arterial pressure without any direct effect 
on CBF. Patients with CHS may have elevated catecho-
lamine concentrations. Therefore, medications like clo-
nidine, a centrally acting sympatholytic, may be useful. 
Blood pressure in patients with CHS should be controlled 
with either labetalol or clonidine, which do not increase 
CBF [2, 3, 19, 21].
Timing of carotid endarterectomy
According to the American Heart Association and 
American Stroke Association Guidelines, the benefit 
of CEA is greatest if it is done within 2  weeks of the 
ischemic stroke or transient ischemic attack [31]. How-
ever, there is a potential risk of CHS and cerebral hem-
orrhage if surgery is done early in patients with large 
cerebral infarction or stroke in evolution. Moreover, in 
the case of bilateral carotid stenosis, the risk of CHS 
is higher in a patient who undergoes CEA in less than 
3  months of the initial procedure on the contralateral 
side. These factors should be taken into account when 
planning CEA [17, 32].
Type of anesthetic
Some of the general anesthetics may lead to cerebral 
hyperperfusion and increase the risk of CHS. Therefore, 
one should be careful when selecting an anesthetic and 
its dose as high doses of a volatile halogenated hydro-
carbon anesthetic may lead to the development of CHS. 
Some anesthetics such as isoflurane are favorable when 
used in patients with cerebral injury as these have a vaso-
dilatory effect on cerebral blood vessels. However, the 
effects of isoflurane on the cerebral metabolic rate and 
cerebral autoregulation are dose dependent, and this 
should be kept in mind as higher doses can potentially 
lead to CHS. Similarly, nitrous oxide is a safe anesthetic 
at a concentration of less than 70  % and has no signifi-
cant effect on cerebral autoregulation. A combination 
of anesthetics may lead to complications. For example, 
nitrous oxide combined with isoflurane may cause cer-
ebral vasodilation. Other anesthetics, such as propofol, 
normalize CBF which may result from its effect on cer-
ebral metabolism, and thus, it can potentially be used in 
patients with CHS [3, 33–35].
Use of anti‑epileptic medications
There is no indication for prophylactic use of anti-epi-
leptic drugs in patients with CHS. However, if a patient 
has periodic lateralized epileptiform discharges on EEG 
or a clinical seizure spell, treatment with an anti-epileptic 
drug may be indicated [2, 3, 36].
Pre‑treatment with free radical scavengers
As mentioned above, oxygen-derived free radicals can 
lead to brain injury in patients with CHS. Free radical 
scavengers such as edaravone may minimize this dam-
age. Edaravone inhibits lipid peroxidation and vascular 
endothelial damage. In one case series, use of edaravone 
helped to reduce the incidence of CHS after CEA as 
measured by SPECT [37]. The evidence for the use of 
antioxidants and free radical scavengers is limited, and 
no definite recommendation about their use in the clini-
cal practice can be made at this time.
Miscellaneous agents: role of mannitol, hypertonic saline, 
and other treatments
In patients with cerebral edema, mannitol and hyper-
tonic saline may be used. However, the evidence for the 
use and potential beneficial effect of these medications 
in patients with CHS and their effect on long-term prog-
nosis is not clear. Other treatments such as corticoster-
oids and barbiturates have been administered in select 
patients. In patients with cerebral edema, adequate seda-
tion and hyperventilation may also be effective [3, 26, 28, 
38]. Similar to what was mentioned in the prior section 
about antioxidants, no definite recommendation can be 
made about the use of mannitol, hypertonic saline, corti-
costeroids and barbiturates in patients with CHS.
Strategies for the prevention and treatment of CHS are 
listed in Table 3.
Conclusion
CHS is a potentially life-threatening complication of 
CEA and carotid stenting. It can happen within a few 
days postoperatively, but presentation can be delayed 
for weeks. Timely diagnosis and treatment are necessary. 
If these patients are treated early, they may do better as 
there may be minimal complications and a good recov-
ery. However, with a delay in diagnosis, the mortality 
rate may be up to 50 %, especially in those patients who 
develop ICH. Patients with CHS may develop headache, 
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focal neurological deficits, cerebral edema, brain hemor-
rhage and seizures. Most of the patients have hyperperfu-
sion. However, a minimal to moderate increase in brain 
perfusion can lead to CHS.
Clinicians should be aware of the main putative risks 
for CHS such as high-grade carotid artery stenosis, poor 
collateral blood flow, post-operative hypertension and 
hyperperfusion, impaired cerebrovascular reserve, intra-
operative distal carotid pressure of <40 mmHg, intraop-
erative ischemia, and recent contralateral CEA. TCD is 
the most commonly and widely available technique used 
in the perioperative period to monitor for cerebral hyper-
perfusion. Control of blood pressure with labetalol and 
clonidine may be useful for the prevention and treatment 
of CHS [2, 3, 18].
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Table 3 Key factors in the prevention and treatment of cerebral hyperperfusion syndrome [1–3, 9, 22, 23, 26, 32, 34, 38]
Treatment modality Comment
Blood pressure control Strict control of blood pressure is recommended
 Lower blood pressure even in normotensive patients
 There are no definite guidelines about blood pressure parameters and management should be individualized
 Avoid medications which have vasodilatory effect such as calcium channel blockers
 Labetalol and clonidine are better options to treat elevated blood pressure in these patients
Timing of carotid surgery  Carotid endarterectomy or stenting should be done within 2 weeks of transient ischemic attack or stroke
 Patient is at risk of cerebral hyperperfusion syndrome if they underwent contralateral carotid endarterectomy 
in past 3 months
Type of anesthetic  High doses of volatile halogenated hydrocarbon anesthetics may lead to cerebral hyperperfusion syndrome
 Isoflurane is safer to use in these patients but can cause complications at higher doses
 Nitrous oxide is also safe but should not be used with isoflurane
 Propofol normalizes cerebral blood flow and is a safe option
Use of anti-epileptic medications  Prophylactic use of an anti-epileptic drug is not recommended
 If patient has lateralized epileptiform discharges or a clinically manifest seizure spell, an anti-epileptic drug may 
be administered
Use of hypertonic saline and mannitol  The evidence about the use of hypertonic saline and mannitol is not strong but may be administered if the 
patient has cerebral edema
 Corticosteroids and barbiturates are not indicated in most cases
 Hyperventilation and sedation may be administered if the patient has cerebral edema
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